NTRP vs TSLA

NTRP exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows explosive year-over-year revenue growth of 1508%, this has failed to translate into profitability, as evidenced by a catastrophic operating margin of -257.04% and an ROE of -680.93%. Liquidity is a primary concern with a current ratio of 0.85 and a quick ratio of 0.55, suggesting the company may struggle to meet short-term obligations. The stock is fundamentally overvalued on a Price/Sales basis (19.00x) despite a long-term price collapse of 95.1% over five years.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.